Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05584254
Other study ID # FODI
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2015
Est. completion date August 14, 2017

Study information

Verified date March 2023
Source Örebro University, Sweden
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators aim was to compare healthy young adults, senior orienteers (model of healthy ageing) and elderly with gastrointestinal symptoms on intestinal permeability, microbiota compositions and well-being. In addition, assess whether 3 weeks of oral intake of soluble or dispersible forms yeast-dervied beta-glucan could improve intestinal barrier function against drug-induced barrier disruption vs placebo for a cohort of elderly people with gastrointestinal symptoms, in a randomized double blinded placebo-controlled cross-over clinical trial.


Description:

Baseline samples for measurements of intestinal permeability (multisugar test), microbiota composition (faecal samples) and well-being (questionnaires) were collected during the first week for: Young healthy adults (healthy young controls) Senior orienteers (healthy elderly controls) Elderly with gastrointestinal (GI) symptoms Thereafter only the elderly with GI symptoms continued into the randomized cross-over trial where they were blindly and randomly distributed one of the following: Soluble yeast-derived beta-glucan, dispersible (whole) yeast-derived beta-glucan and placebo. Each supplement was taken for 3 weeks with a 1 week washout until all participants had taken all supplements. Towards the end of each supplement period, samples for measurement of intestinal permeability and microbiota were collected, in addition to questionnaires being filled out.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date August 14, 2017
Est. primary completion date August 14, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 55 Years to 100 Years
Eligibility Elderly with gastrointestinal symptoms Inclusion Criteria: - Informed consent signed by study participant - Age >55 years - Scoring above 2 on the dimensions for diarrhoea and constipation on the Gastrointestinal symptoms rating scale (GSRS) - Mentally and physically fit to complete questionnaires during the study period Exclusion Criteria: - Known or genic gastrointestinal diseasewith strictures, malignance's and ischemia. - Inflammatory bowel diseases (IBD) - Participation in other clinical trials in the past three months. - Intake of medications know to change the inflammatory status (i.e proton pump inhibitors, antibiotic, anti-inflammtory medication (including NSAIDs) Healthy controls Inclusion Criteria: - Age = 18 years - Informed consent signed by the study participant - Mentally and physically fit to complete questionnaires during the study period Exclusion Criteria: - Previous abdominal surgery - A hypertonic condition demanding medical treatment - Diagnosed psychiatric disease - Lactose intolerance - Usage of medical prescribed medications, expect oral contraceptives, during the 14 days preceding study start - Premenstrual syndrome - Pregnant or breast feeding - Known or genic gastrointestinal disease, with strictures, malignance's and ischemia. - Inflammatory bowel diseases (IBD) - Participation in other clinical trials in the past three months.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
yeast-beta glucan


Locations

Country Name City State
Sweden Campus USÖ, Örebro University Örebro

Sponsors (2)

Lead Sponsor Collaborator
Örebro University, Sweden Kerry Group

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intestinal permeability at baseline (before indomethacin) In vivo gastrointestinal permeability measured by oral intake of multi-sugar test before intake of indomethacin. Urine collected over 24 hours for measurement of excreted sugars. Day 1
Primary Intestinal permeability at baseline (after indomethacin) In vivo gastrointestinal (GI) permeability measured by oral intake of multi-sugar test after intake of indomethacin (GI barrier disruption challenge). Urine collected over 24 hours for measurement of excreted sugars. Day 1
Primary Changes in Intestinal permeability 3 weeks after study supplementation 1 (before indomethacin). Performed after study participants have orally taken study supplementation 1 for 3 weeks. In vivo gastrointestinal permeability measured by oral intake of multi-sugar test before intake of indomethacin. Urine collected over 24 hours for measurement of excreted sugars. 3 weeks
Primary Changes in intestinal permeability 3 weeks after study supplementation 1 (after indomethacin). Performed after study participants have orally taken study supplementation 1 for 3 weeks.
In vivo gastrointestinal (GI) permeability measured by oral intake of multi-sugar test after intake of indomethacin (GI barrier disruption challenge). Urine collected over 24 hours for measurement of excreted sugars.
3 weeks
Primary Changes in intestinal permeability 3 weeks after study supplementation 2 (before indomethacin) Performed after study participants have orally taken study supplementation 2 for 3 weeks.
In vivo gastrointestinal permeability measured by oral intake of multi-sugar test before intake of indomethacin. Urine collected over 24 hours for measurement of excreted sugars.
3 weeks
Primary Changes in intestinal permeability 3 weeks after study supplementation 2 (after indomethacin) Performed after study participants have orally taken study supplementation 2 for 3 weeks.
In vivo gastrointestinal (GI) permeability measured by oral intake of multi-sugar test after intake of indomethacin (GI barrier disruption challenge). Urine collected over 24 hours for measurement of excreted sugars.
3 weeks
Primary Changes in intestinal permeability 3 weeks after study supplementation 3 (before indomethacin) Performed after study participants have orally taken study supplementation 3 for 3 weeks.
In vivo gastrointestinal permeability measured by oral intake of multi-sugar test before intake of indomethacin. Urine collected over 24 hours for measurement of excreted sugars.
3 weeks
Primary Changes in intestinal permeability 3 weeks after study supplementation 3 (after indomethacin) Performed after study participants have orally taken study supplementation 3 for 3 weeks.
In vivo gastrointestinal (GI) permeability measured by oral intake of multi-sugar test after intake of indomethacin (GI barrier disruption challenge). Urine collected over 24 hours for measurement of excreted sugars.
3 weeks
Secondary Microbiota diversity - at baseline Faecal samples will be used for next-generation sequencing and analysed for diversity Day 1
Secondary Bacterial species - at baseline Faecal samples will be used for next-generation sequencing and analysed for bacterial species Day 1
Secondary Changes in microbiota diversity 3 weeks after study supplementation 1 Faecal samples will be used for next-generation sequencing and analysed for changes in microbiota diversity 3 weeks
Secondary Changes in bacterial species 3 weeks after study supplementation 1 Faecal samples will be used for next-generation sequencing and analysed for changes in bacterial species levels 3 weeks
Secondary Changes in microbiota diversity 3 weeks after study supplementation 2 Faecal samples will be used for next-generation sequencing and analysed for changes in microbiota diversity 3 weeks
Secondary Changes in bacterial species 3 weeks after study supplementation 2 Faecal samples will be used for next-generation sequencing and analysed for changes in bacterial species levels 3 weeks
Secondary Changes in microbiota diversity 3 weeks after study supplementation 3 Faecal samples will be used for next-generation sequencing and analysed for changes in microbiota diversity 3 weeks
Secondary Changes in bacterial species 3 weeks after study supplementation 3 Faecal samples will be used for next-generation sequencing and analysed for changes in bacterial species levels 3 weeks
Secondary Changes in microbiota diversity - Washout (1 week after ending supplementation 1, i.e. 4 weeks after baseline) Faecal samples will be used for next-generation sequencing and analysed for changes in microbiota diversity from 1 weeks washout, after ending study supplementation 1 (4 weeks after baseline) 4 weeks
Secondary Changes in bacterial species - Washout (1 week after ending study supplementation 1, i.e. 4 weeks after baseline) Faecal samples will be used for next-generation sequencing and analysed for changes in bacterial species from 1 weeks washout, after ending study supplementation 1 (4 weeks after baseline) 4 weeks
Secondary Changes in microbiota diversity - Washout (1 week after ending study supplementation 2, i.e. 4 weeks after baseline) Faecal samples will be used for next-generation sequencing and analysed for changes in microbiota diversity from 1 weeks washout, after ending study supplementation 2 (4 weeks after baseline) 4 weeks
Secondary Changes in bacterial species - Washout (1 week after ending study supplementation 2, i.e. 4 weeks after baseline) Faecal samples will be used for next-generation sequencing and analysed for changes in bacterial species from 1 weeks washout, after ending study supplementation 2 (4 weeks after baseline). 4 weeks
Secondary Changes in microbiota diversity - Washout (1 week after ending study supplementation 3, i.e. 4 weeks after baseline) Faecal samples will be used for next-generation sequencing and analysed for changes in microbiota diversity from 1 weeks washout, after ending study supplementation 3 (4 weeks after baseline) 4 weeks
Secondary Changes in bacterial species - Washout (1 week after ending study supplementation 3, i.e. 4 weeks after baseline) Faecal samples will be used for next-generation sequencing and analysed for changes in bacterial species from 1 weeks washout, after ending study supplementation 3 (4 weeks after baseline) 4 weeks
Secondary Changes in gastrointestinal symptom questionnaire scores The Gastrointestinal Symptoms Rating Scale (GSRS) evaluates gastrointestinal (GI) symptoms based on the 5 domains diarrhoea, constipation, reflux, indigestion and abdominal pain. The symptoms are assessed with 15 items, ranging in scores 1 to 7 depending on their severity. A score of 1 represents "no problems" and score 7 represents "severe problems". The severity of symptoms may be defined as no problems (1 point), mild (1-2 points), moderate (2-4 points), and severe (4-7 points). The scores for each domain was calculated as the mean score of each corresponding item while the mean total GSRS score reflects the general severity of GI symptoms. up to 13 weeks
Secondary Changes in hospital and anxiety depression scores The Hospital Anxiety and Depression Scale (HADS) was used to evaluate the psychological distress of study participants.This questionnaire consists of 14 items subdivided in two subscales for the assessment of anxiety or depression. The total score is used as a measure of general psychological distress. The minimum score is 0 and the maximum score is 21. A score > 8 on respective subscales indicates a significant level of anxiety or depression. up to 13 weeks
Secondary Changes in perceived stress scale scores The perceived stress scale (PSS) consists of 10 items, including a number of direct questions about current levels of experienced stress. The respondent answers how often a certain emotion has been present during the past month. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the four positively stated items (items 4, 5, 7, & 8) and then summing across all scale items. Each item is rated on a 5-point scale ranging from never (0) to almost always (4). The questions in this scale ask about the responders feelings and thoughts during the last month. In each case the questionnaire requires the respondent to indicate by circling how often they felt or thought a certain way. Up to 13 weeks
Secondary Changes in quality of life questionnaire scores The EuroQol 5D-5L (EQ-5D-5L) tool consists of two parts; 5Q-5D, which includes 5 items related to wellbeing and function (mobility, self-care, usual activities, pain/discomfort and anxiety/ depression) and the visual analogue scale, 5Q-5D-VAS, ranging from 0 to 100. Up to 13 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05531396 - Agility Training on Physical Performance, Cognitive Function and Brain Activities in Elderly N/A
Completed NCT03580447 - The Effect of Citrus Extract on Oxidative Stress N/A
Recruiting NCT04096547 - Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment
Completed NCT03339791 - Sleeve Versus Bypass in Older Patients: a Randomized Controlled Trial N/A
Completed NCT03566719 - Effect of an Exercise Program on Risk of Fall in a Community Dwelling Older Adults N/A
Completed NCT02138968 - Clinical and Economic Assessment of a Pre-frail Screening Program N/A
Completed NCT01368029 - Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine Phase 1
Not yet recruiting NCT01182961 - The Use of Virtual Reality for the Gait Training of Elderly Fallers N/A
Completed NCT01899586 - Mechanisms and Functional Outcomes of Exercise Progression Models in the Elderly N/A
Completed NCT00961012 - The Big Squeeze (Lessening the Big Squeeze: The Effect of the Trunk Release on Interface Pressures of Individuals Seated in a High Fowler's Positions) N/A
Completed NCT00748683 - Development of an Integrated Health Care Environment for Elderly With RFID Technology Phase 0
Completed NCT00533065 - Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone N/A
Completed NCT00324701 - Telepsychology-Service Delivery for Depressed Elderly Veterans N/A
Completed NCT00798668 - The Body's Response to Food Intake in Trained, Older Adults N/A
Completed NCT00217113 - An Intervention to Preserve Functional Status and Independence Among Community Dwelling Elderly N/A
Completed NCT03666793 - Comprehensive Management of Drug Prescriptions Throughout the Elderly Person's Hospital Care N/A
Recruiting NCT06030804 - Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery N/A
Recruiting NCT05014750 - Frailty of Elderly With Valvular Heart Disease and the Short Term Adverse Events
Completed NCT05021432 - Virtual Reality And Task Oriented Circuit Training Among Elderly Population N/A
Active, not recruiting NCT04132492 - AGNES - Aging Nephropathy Study, a Prospective Observational Cohort of Chronic Kidney Disease in Elderly Patients